The IFEMA Convention Centre hosts the 22nd edition of the Spanish Society of Hypertension-Spanish League for the Fight against Arterial Hypertension Assembly (SEH-LELHA) from 29 to 31 March 2017. This is the leading meeting on the subject of research into Cardiovascular Risk Prevention and its management in everyday clinical practice.
The College of Nursing (EHRICA) will attend the event, together with the Investigators into Vascular Pathophysiology (RIFV) and the Community Pharmacists (SEFAC). These groups will give their professional audience a comprehensive overview of cardiovascular disease, from the pathophysiological mechanisms involved through to clinical practice, as well as the community's involvement in chronic illness.
The Scientific Committee of the Spanish Society of Hypertension-Spanish League for the Fight against Arterial Hypertension has assessed and selected 214 scientific communications, 69 of which will be presented, orally, during the three-day event. The themed areas will be: preclinical research, epidemiology, blood pressure measurement: MAPA, AMPA, central blood pressure and pulse pressure, clinical hypertension and co-morbidity, high blood pressure and women, metabolic syndrome, pre-diabetes and diabetes, target organ damage, risk stratification, clinical trials, and non-pharmacological treatment, pharmacological treatment, compliance and inertia and nursing
The National SEH - LELHA meeting will kick off on 29 March, with a pre-congress course on “Cardiovascular Risk Prevention. What’s new?” This will be followed by a busy line-up of professional meetings including panel discussions, workshops and plenary sessions, which will offer a broad view of advances in the field of
hypertension; their future; as well as the different groups of patients and their characteristics.
The following matters will be addressed at the 22nd edition of the Spanish Society of Hypertension-Spanish League for the Fight against Arterial Hypertension Assembly (SEH-LELHA): preclinical research, epidemiology, blood pressure measurement: MAPA, AMPA, central blood pressure and pulse pressure, clinical hypertension and co-morbidity, high blood pressure and women, metabolic syndrome, pre-diabetes and diabetes, target organ damage, risk stratification, clinical trials, and non-pharmacological treatment, pharmacological treatment, compliance and inertia and nursing.
According to data published by the Spanish Society of Hypertension-Spanish League for the Fight against Arterial Hypertension Assembly (SEH-LELHA), there are more than 14 million people with hypertension in Spain. Of these, 9.5 million are not controlled and 4 million are undiagnosed.
Cardiovascular disease is the main cause of death in Spain. However, hypertension is a treatable disease. If patients do not follow the medical recommendations, they may suffer from serious complications, such as myocardial infarction, cerebral haemorrhage or thrombosis, which can be avoided if properly controlled. The arteries suffer the first consequences of hypertension, which harden to as they support continuous high blood pressure, thickening and hindering blood flow. This is known as arteriosclerosis.
Although the specific causes of hypertension are unknown, if it has been linked to several factors that are tend to be present in sufferers. It is important to separate those related to genetics, gender, age, and race and therefore those which can be influenced by changing our habits, environment, and customs, such as: obesity, sodium sensitivity, excessive alcohol consumption, use of oral contraceptives and a sedentary lifestyle.
